Logo

Roche: Andreas Oeri, John Bell

Dec 09, 2019

Roche announced Andreas Oeri will retire from the company's board of directors in 2020, to be replaced by Jörg Duschmalé. Oeri was previously chairman of the company's corporate governance and sustainability committee. Also, the company said that John Bell will not stand for reelection to the board in 2020, and the board has proposed Patrick Frost, CEO of the Swiss Life Group, for his replacement. 

Additionally, Gottlieb Keller, Roche's general counsel, a member of the corporate executive committee, and the board's secretary, will retire in March 2020 after 35 years at the company. Claudia Böckstiegel, who is currently the head of legal of Roche's diagnostics division, will take over as general counsel. On April 1, 2020, she will also become a member of the Enlarged Corporate Executive committee. Annette Luther, the current general manager of Roche Diagnostics International, will be the new secretary to the board. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.